Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qing Ding

Showing results (431-440 of 435) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 435 results.
Nature Communications|September 18, 2023
Retraction Note: Mir20a/106a-WTX axis regulates RhoGDIa/CDC42 signaling and colon cancer progressionGui-Fang Zhu, Yang-Wei Xu, Jian Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast CancerClinton Yam, Er-Yen Yen, Jeffrey T Chang, et al.
Frontiers in Oncology|March 13, 2023
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)Xiao-Dong Jiao, Bao-Dong Qin, Zhan Wang, et al.
Cell Research|June 17, 2021
A cohort autopsy study defines COVID-19 systemic pathogenesisXiao-Hong Yao, Tao Luo, Yu Shi, et al.
Cancer Research Communications|October 2, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II StudyClinton Yam, Miral Patel, Holly A Hill, et al.
Pageof 44

Showing results (431-440 of 435) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 435 results.
Nature Communications|September 18, 2023
Retraction Note: Mir20a/106a-WTX axis regulates RhoGDIa/CDC42 signaling and colon cancer progressionGui-Fang Zhu, Yang-Wei Xu, Jian Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast CancerClinton Yam, Er-Yen Yen, Jeffrey T Chang, et al.
Frontiers in Oncology|March 13, 2023
Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)Xiao-Dong Jiao, Bao-Dong Qin, Zhan Wang, et al.
Cell Research|June 17, 2021
A cohort autopsy study defines COVID-19 systemic pathogenesisXiao-Hong Yao, Tao Luo, Yu Shi, et al.
Cancer Research Communications|October 2, 2024
Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II StudyClinton Yam, Miral Patel, Holly A Hill, et al.
Pageof 44